MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Rezdiffra
Pharma

Madrigal embraces Novo competition as MASH drug gains steam

Throughout 2025, the world's first metabolic dysfunction-associated steatohepatitis (MASH) drug generated just shy of a billion dollars.
Zoey Becker Feb 19, 2026 2:16pm
Asia

Lilly-Innovent, AstraZeneca, Madrigal—Fierce Pharma Asia

Feb 13, 2026 8:25am
Rezdiffra

Madrigal's MASH drug Rezdiffra posts 35% sales increase in Q3

Nov 5, 2025 12:02pm
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am
Wegovy

Novo's Wegovy in line for a 'swift' adoption in MASH: Spherix

Aug 29, 2025 11:40am
liver

With key FDA nod in MASH, Novo's Wegovy scores 3rd indication

Aug 18, 2025 10:08am